Thursday, September 25, 2008

UCB Withdraws EU Marketing Authorisation Application for Lacosamide in Diabetic Neuropathic Pain

UCB announced today that it is withdrawing the European Marketing Authorisation Application with the European Medicines Agency (EMEA) for Vimpat® (lacosamide) in the treatment of diabetic neuropathic pain.

The details can be read here.
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)